Real-Life Experience of Regorafenib in Patients With Advanced Hepatocellular Carcinoma

Background: The RESORCE trial reported that regorafenib was effective as the second-line treatment for patients with hepatocellular carcinoma (HCC) after progression on sorafenib. Real-world data are needed to assess clinical outcomes and adverse events in the setting of daily practice. Objective: W...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Jing-Yu, Xiao, Ya-ting, Huang, Jing-Bo, Jiang, Xin-Hua, Jiang, Kai, Li, Xun, Xu, Li, Chen, Min-Shan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207200/
https://www.ncbi.nlm.nih.gov/pubmed/35734398
http://dx.doi.org/10.3389/fphar.2022.917384

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207200/
https://www.ncbi.nlm.nih.gov/pubmed/35734398
http://dx.doi.org/10.3389/fphar.2022.917384

Ejemplares similares